Compare TKNO & KIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TKNO | KIO |
|---|---|---|
| Founded | 1996 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 482.7M | 455.8M |
| IPO Year | 2021 | 2011 |
| Metric | TKNO | KIO |
|---|---|---|
| Price | $7.33 | $10.02 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $9.67 | N/A |
| AVG Volume (30 Days) | ★ 651.2K | 339.8K |
| Earning Date | 11-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.86 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $40,520,000.00 | N/A |
| Revenue This Year | $13.54 | N/A |
| Revenue Next Year | $14.51 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.35 | N/A |
| 52 Week Low | $1.91 | $9.70 |
| 52 Week High | $9.48 | $12.12 |
| Indicator | TKNO | KIO |
|---|---|---|
| Relative Strength Index (RSI) | 48.37 | 41.47 |
| Support Level | $4.89 | $9.74 |
| Resistance Level | $7.66 | $11.26 |
| Average True Range (ATR) | 0.64 | 0.11 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 74.07 | 70.97 |
Alpha Teknova Inc is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Its offer two primary product categories: Lab Essentials and Clinical Solutions. It derives key revenue from the United States. The company offers three primary product types: (i) pre-poured media plates for cell growth and cloning; (ii) liquid microbial culture media and supplements for cellular expansion; and (iii) molecular biology reagents for sample manipulation, resuspension, and purification.
KKR Income Opportunities Fund operates as a closed-end registered management investment company. The Fund's main objective is to generate a high level of current income, with a secondary objective of capital appreciation. The company invests in a portfolio of loans and fixed-income instruments of U.S. and non-U.S. issuers. The company will invest at least 80% of its Managed Assets in loans and fixed-income instruments or other instruments, including derivative instruments, with similar economic characteristics under normal market conditions.